KT A112
Alternative Names: AAV-Ins+Gck; KT-A112Latest Information Update: 28 Jun 2024
At a glance
- Originator Kriya Therapeutics
- Class Antihyperglycaemics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (IM, Injection)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (IM, Injection)
- 23 Jun 2023 Pharmacodynamics data from a preclinical studies in Type 1 diabetes mellitus presented at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA-2023)